← Leaderboards
Julio C Barredo
Medical University Of South Carolina
$2,310,603
Attributed
$2,310,603
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $776.5K · FY2005–08$1M$750K$500K$250K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$2,310,603 · 5
By mechanism
R01$1,495,462 · 1
N01$479,135 · 1
R29$203,985 · 1
U10$111,736 · 1
M01$20,285 · 1
Top collaborators
No co-investigators on record.
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Joseph Laver$123,721
Others in their field
Top investigators on “Methotrexate”
- Paul M. Ridker · Brigham And Women'S Hospital$55,416,022
- Norman Wolmark · Nsabp Foundation, Inc.$52,338,276
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Mary V. Relling · St. Jude Children'S Research Hospital$14,849,481
- Janet T. Holbrook · Johns Hopkins University$12,837,055
- Keri, Hammel · The Emmes Company, Llc$11,064,901
Research focus
MethotrexateNeoplasm /Cancer ChemotherapyHuman SubjectClinical ResearchHuman Therapy EvaluationAcute Lymphocytic LeukemiaDrug MetabolismGene ExpressionDrug ResistanceTetrahydrofolylpolyglutamate SynthaseAcute LeukemiaPhenotypePediatric PharmacologyGliomaCytotoxicityColony Stimulating FactorNeoplasm /Cancer PharmacologySingle Nucleotide PolymorphismAdolescence (12-20)Child (0-11)Drug Screening /EvaluationAstrocytomaAsparaginaseAntineoplastics
Grant awards (13)
Molecular Determinants of Methotrexate in Acute Lymphoblastic Leukemia$297,398
R01 · FY2008 · CA · contact PI
PEDIATRIC HYDROXYUREA PHASE III CLINICAL TRIAL$479,135
N01 · FY2007 · HL · contact PI
Molecular Determinants of Methotrexate in Acute Lymphoblastic Leukemia$297,317
R01 · FY2007 · CA · contact PI
Molecular Determinants of Methotrexate in ALL$231,800
R01 · FY2006 · CA · contact PI
Molecular Determinants of Methotrexate in ALL$70,347
R01 · FY2006 · CA · contact PI
Molecular Determinants of Methotrexate in ALL$299,300
R01 · FY2005 · CA
PEDIATRIC HYDROXYUREA PHASES III CLINICAL TRIAL - BABY HUG$17,152
M01 · FY2005 · RR
Molecular Determinants of Methotrexate in ALL$299,300
R01 · FY2004 · CA
Pediatric Hydroxyurea Phase III Clinical Trial$3,133
M01 · FY2004 · RR
PEDIATRIC ONCOLOGY GROUP--THE CAROLINAS CONSORTIUM$61,584
U10 · FY2002 · CA
CLINICAL PHENOTYPE TARGETED ANTIFOLATE CHEMOTHERAPY$102,266
R29 · FY2001 · CA
PEDIATRIC ONCOLOGY GROUP--THE CAROLINAS CONSORTIUM$50,152
U10 · FY2001 · CA
CLINICAL PHENOTYPE TARGETED ANTIFOLATE CHEMOTHERAPY$101,719
R29 · FY2000 · CA